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Effect of Aspirin on the Expression of Hepatocyte NF-κB and 
Serum TNF-α in Streptozotocin-Induced Type 2 Diabetic Rats
Aspirin is a kind of anti-inflammatory drug and may be used to reverse hyperglycemia, 
hyperinsulinemia, and dyslipidemia by improving insulin resistance. We hypothesized that 
aspirin improves insulin resistance in type 2 diabetes by inhibiting hepatic nuclear factor 
kappa-β (NF-κB) activation and serum tumor necrosis factor-α (TNF-α). Adult male Wistar 
rats were randomly divided into four groups: control, untreated diabetic, diabetic treated 
with metformin (100 mg /kg/day), and diabetic treated with aspirin (120 mg/kg/day). 
Diabetes was induced by high-fat feeding and a low dose of streptozotocin (30 mg/kg). 
After treatment, plasma glucose, insulin, lipids, free fatty acids (FFAs) concentrations and 
serum TNF-α were determined. The expression of NF-κB in hepatocytes was analyzed by 
immunohistochemistry and western blot. The results showed administration of aspirin 
caused no significant lowering in fasting glucose level but significant reduction of hepatic 
NF-κB expression and serum TNF-α level with improved insulin resistance compared to the 
diabetic group. The relevant analysis showed positive correlation between the expression of 
homeostasis model assessment-insulin resistance (HOMA-IR) and NF-κB (r = 0.799, P < 
0.01); HOMA-IR and serum TNF-α (r = 0.790, P < 0.01). It is concluded that aspirin 
improves insulin resistance by inhibiting hepatic NF-κB activation and TNF-α level in 
streptozotocin-induced type 2 diabetic rats.
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INTRODUCTION
A lot of evidence suggests that, insulin resistance, defined as a 
state of reduced insulin action in peripheral tissues, such as the 
skeletal muscle, adipose tissue, and liver, plays a critical role in 
the development and onset of type 2 diabetes (1, 2). In recent 
years, more evidence has emerged that proinflammatory cyto-
kines can cause sustained development of insulin resistance (3) 
and anti-inflammatory medications may reverse the process of 
it (4, 5). A number of epidemiological studies and animal re-
search have shown a correlation between insulin resistance and 
inflammatory markers such as tumor necrosis factor-α (TNF-α), 
C-reactive protein (CRP) and interleukin-6 (IL-6) (6, 7), suggest-
ing that inflammation may be directly involved in the pathogen-
esis of insulin resistance. TNF-α, produced by adipocytes and 
macrophages, has been implicated to play an important role in 
the cascade of inflammation, systemic insulin resistance, reduced 
β-cell secretion of insulin, and thus type 2 diabetes (8). Nuclear 
factor kappa-β (NF-κβ) is a nuclear transcriptional activator that 
also plays a central role in the inflammation. Recently there were 
two studies supporting the important function of NF-κB in in-
sulin resistance. Elevated expression of the IKK-β (NF-κB kinase) 
in hepatic cells caused profound hepatic insulin resistance and 
more moderate systemic insulin resistance in mice (9). Mice 
lacking IKK-β in hepatocytes retained global insulin sensitivity 
and were protected from insulin resistance in response to high-
fat diet, obesity, or aging (10). Substantial evidence indicates that 
aspirin, a kind of non-steroidal anti-inflammatory drug (NSAIDs), 
has antipyretic, analgesic and anti-inflammatory effects. 
  Recent studies indicated that aspirin might be an insulin-sen-
sitizing agent and they may be used to reverse hyperglycemia, 
hyperinsulinemia, and dyslipidemia by sensitizing insulin sig-
naling and improving insulin resistance (4). However, the cellu-
lar and molecular mechanisms of aspirin in improving insulin 
resistance in type 2 diabetes have not been well elucidated. We 
therefore hypothesized that aspirin improves insulin resistance 
in type 2 diabetes by inhibiting NF-κB activation and TNF-α lev-
els. To test this hypothesis, we examined the effect of aspirin on 
hepatic NF-κB activation and its downstream target gene TNF-α 
in rat model of type 2 diabetes induced by high-carbohydrate-
fat diet and streptozotocin (STZ).
MATERIALS AND METHODS 
Materials
STZ was purchased from Sigma (St. Louis, MO, USA); insulin 
was purchased from Eli Lilly (Changchun, China); glucose, total 
cholesterol (TC), and triglyceride (TG) test kits were obtained Sun X, et al.  •  Effect of Aspirin on Hepatocyte NF-κB and Serum TNF-α 
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from Beijing BHKT Clinical Reagent Co., Ltd. (Beijing, China); 
iodine [
125I] insulin radioimmunoassay kit was purchased from 
Tianjin Nine Tripods Medical & Bioengineering Co., Ltd. (Tian-
jing, China). Other reagents were purchased from Beijing Gen-
eral Chemical Reagent Factory (Beijing, China). Western blot 
kits for NF-κB, and kits for TNF-α were from Wuhan Boster Bio-
logical Engineering Co., Ltd. (Wuhan, China) and Nanjing Ji-
ancheng Biological Engineering Research Institute (Nanjing, 
China), respectively.
Experimental animal 
Six-week-old male Wistar rats were purchased from the Experi-
mental Animal Center of Shandong University. The use of ani-
mals in these experiments received institutional animal care and 
use committee (IACUC) approval (approval No. SCU20090606). 
The animals were housed under standard laboratory conditions 
and maintained under controlled room temperature and humid-
ity with a cycle of 12 hr of light and 12 hr of dark. All rats were 
randomly divided into two groups: normal control group and 
diabetic model group. The normal control group was fed with 
regular diet (8% fat, 68% carbohydrate, 24% protein, 320 kcal 
100 g/L) and the others were fed with high-fat diet (60% fat, 20% 
carbohydrate, and 20% protein, 560 kcal 100 g/L). Eight weeks 
later, the diabetic model group were received intraperitoneal 
injection with a low dose of STZ (30 mg/kg) while the control 
group were given vehicle citrate buffer (pH 4.4) in a dose volume 
of 0.25 mL/kg, respectively. This diabetic model was similar to 
type 2 diabetes in human, where the high-fat diet intake initiat-
ed a state of insulin resistance and then the treatment of the rel-
atively low dose of STZ established a relative insulin deficiency 
(11). The diabetic model group was further randomly divided 
into three groups: diabetic group, metformin-treated group, and 
aspirin-treated group. Metformin-treated group were adminis-
tered to metformin (100 mg/kg/day) and aspirin-treated group 
were treated with aspirin (120 mg/kg/day) (12). Control group 
and diabetic control group were given the same amount of wa-
ter. The rats were sacrificed after treatment of 8 weeks. The livers 
were perfused and collected in formalin for immunohistochem-
istry. The remaining liver tissues were fresh-frozen in liquid ni-
trogen for protein analysis. 
Plasma measurements
Blood was sampled by intracardiac puncture. Plasma triglycer-
ide (TG), cholesterol (TC), low density lipoprotein (LDL), high 
density lipoprotein (HDL) and free fatty acids (FFAs) concen-
trations were determined by using colorimetric assays. Plasma 
insulin was assayed by radioimmunoassay according to the in-
struction. The concentrations of serum TNF-α was measured by 
radioimmunoassay with an automatic biochemical analytic in-
strument. The marker of insulin resistance was evaluated by 
homeostasis model assessment estimate of insulin resistance 
(HOMA-IR) (13) as follows: fasting plasma insulin (μU/mL) × 
fasting glucose (mM/L)/22.5.
Histology and immunohistochemistry
An equal liver sample from each rat (1 × 1 × 0.5 cm) was fixed in 
40 g/L formaldehyde for 48 hr, embedded in paraffin, and sec-
tioned. The 5 µm sections were stained with hematoxylin and 
eosin for general histopathological examination. Tissues were 
dissected and fixed in formalin overnight. Formalin-fixed tissues 
were sectioned and used for immunohistochemistry reveal NF-
κB in hepatic tissues. Tissue sections of 5 µm were deparaffinized 
in xylene and rehydrated in ethanol followed by water and phos-
phate-buffered saline. Endogenous peroxidase was blocked by 
immersion in 3% hydrogen peroxide. The tissue sections were 
then incubated with NF-κB antibodies at a concentration of 5 
µg/mL for 1 hr at room temperature. Control sections were in-
cubated with phosphate-buffered saline containing normal goat 
serum without a primary antibody. Immunostaining was then 
detected with a streptavidin-biotin complex (SABC) kit and de-
veloped with diaminobenzidine tetrahydrochloride. The sec-
tions were counterstained with hematoxylin followed by light 
microscopy.
Western blot analysis 
Total protein was extracted according to the manufacturer’s in-
structions. For NF-κB, a KEYGEN nuclear-cytosol protein extrac-
tion kit was used. Western blot was performed according to the 
manufacturer’s procedures. Sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) was performed by the 
method of Laemmli (14) with a mini-slab apparatus. Sample of 
50 µg protein was added to each lane. After polyacrylamide gel 
electrophoresis, the proteins were transferred onto nitrocellu-
lose membranes. For protein signal detection, the samples were 
blocked with a solution of tris-buffered saline containing 5% fat-
free milk and 0.1% Tween-20 (TBST) at room temperature for   
1 hr, probed with anti-NF-κB antibody, and washed three times 
in TBST. The membranes were incubated with alkaline phospha-
tase-conjugated secondary antibody for 2 hr at room tempera-
ture and washed three times with TBST. Products were stained 
with nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phos-
phate and scanned and quantified using Pro-plus 5.0 image-
processing system to determine the gray scale value.
Statistical analysis 
All data were subjected to statistical analysis by using SPSS 16.0 
statistical package. The data were expressed as mean ± standard 
deviation (SD). Statistical analysis was performed by one way 
ANOVA. The number of inter-group differences were performed 
using Student-Newman-Keuls test. Relationship between two 
variables was analyzed by Pearson’s correlation. P value of less 
than 0.05 was considered statistically significant.Sun X, et al.  •  Effect of Aspirin on Hepatocyte NF-κB and Serum TNF-α 
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RESULTS
Plasma parameters
The results of the present work showed development of insulin 
resistance in the diabetic group, which was expressed as a sig-
nificant increase in HOMA-IR when compared to the control 
group (7.07 ± 1.88 vs 2.22 ± 0.26; P < 0.001). When compared to 
the control group, the diabetic group showed significant increase 
in serum levels of fasting glucose (9.82 ± 1.21 vs 4.78 ± 0.31; P < 
0.001), insulin (15.95 ± 2.72 vs 10.43 ± 0.74; P < 0.001), FFAs (825.30 
± 93.39 vs 202.82 ± 85.43), TG (2.07 ± 0.28 vs 0.78 ± 0.29; P < 0.001) 
and TNF-α (75.30 ± 8.09 vs 25.74 ± 3.84; P < 0.001) (Table 1).
  Aspirin-treated group showed significant reduction of the fol-
lowing studied parameters when compared to the diabetic group: 
insulin (11.74 ± 2.87 vs 15.95 ± 2.72, P < 0.001), HOMA-IR (4.85 ± 
1.78 vs 7.07 ± 1.88, P < 0.001), FFAs (624.57 ± 98.67 vs 825.30 ± 
93.39) and TNF-α (44.97 ± 4.67 vs 75.30 ± 8.09, P < 0.001), respec-
tively. However, there is no significance difference in fasting glu-
cose (9.04 ± 1.19 vs 9.82 ± 1.21, P = 0.353)
  The metformin-treated group showed significant reduction of 
the following parameters when compared to the diabetic group: 
fasting glucose (7.66 ± 0.82 vs 9.82 ± 1.21, P < 0.001), insulin (13.89 
± 2.34 vs 15.95 ± 2.72, P < 0.001), HOMA-IR (4.79 ± 1.23 vs 7.07 ± 
1.88, P < 0.001) and FFAs (713.35 ± 104.58 vs 825.30 ± 93.39), re-
spectively. However, there was no significant change in TNF-α 
(75.75 ± 5.60 vs 75.30 ± 8.09, P = 0.754).
Histology and immunohistochemistry
Hepatocytes, separated from the sinusoids, were large polyhe-
dral cells with round nuclei in control group, (hematoxylin and 
eosin stain, × 75). Hepatocytes became larger; and red-stained 
granules within cytoplasm showed glycogen deposition in the 
Table 1. Values of HOMA-IR and serum levels fasting glucose, insulin, FFA, lipids and TNF-α in the studied groups (n = 9)
Parameters Control group Diabetic group Apirin-treated group Metformin-treated group
Fasting glucose (mM/L) 4.78 ± 0.31 9.82 ± 1.21* 9.04 ± 1.29* 7.66 ± 2.86*
,†
Fasting insulin (μIU/mL) 10.43 ± 0.74 15.95 ± 2.72* 11.74 ± 2.87*
,† 13.89 ± 2.86*
,†
HOMA-IR 2.22 ± 0.26 7.07 ± 1.88* 4.82 ± 1.82*
,† 4.79 ± 1.40*
,†
FFA (μM/L) 202.82 ± 85.43 825.30 ± 93.39* 624.57 ± 98.67*
,†,‡ 713.35 ± 104.58*
,†
TNF-α (pg/mL) 25.74 ± 3.84 75.30 ± 8.09* 44.97 ± 4.67*
,†,‡ 75.75 ± 5.60*
TG (mM/L) 0.78 ± 0.29 2.07 ± 0.28* 1.29 ± 0.29*
,†,‡ 1.82 ± 0.26*
,†
CHO (mM/L) 1.49 ± 0.24 1.54 ± 0.33 1.58 ± 0.31 1.51 ± 0.35
LDL (mM/L) 0.340 ± 0.04 0.360 ± 0.04 0.342 ± 0.03 0.338 ± 0.05
HDL (mM/L) 1.03 ± 0.21 1.14 ± 0.19 1.12 ± 0.17 1.18 ± 0.18
Data are shown as mean ± SD. *P < 0.001, compared to control group; 
†P < 0.001, compared to diabetic group; 
‡P < 0.05, compared to metformin-treated group. 
A D C B
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Fig. 1. HE staining and NF-κB expression of liver tissues from four studied groups. (A) HE staining in NC group. (B) HE staining in diabetic group. (C) HE staining in aspirin-treated 
group. (D) HE staining in metformin–treated group. (E) NF-κB expression in NC group. (F) NF-κB expression in diabetic group. (G) NF-κB expression in aspirin-treated group. (H) 
NF-κB expression in metformin–treated group (× 400). Sun X, et al.  •  Effect of Aspirin on Hepatocyte NF-κB and Serum TNF-α 
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other three groups. Hepatic sinusoids became slightly thinner 
(Fig. 1). Hepatocyte NF-κB was mainly expressed in the cyto-
plasm and weakly expressed in the nuclei in the control group. 
Hepatocyte NF-κB was expressed both in the cytoplasm and 
nuclei in the diabetic group and the metformin-treated group. 
But in the aspirin-treated group, hepatocyte NF-κB expression 
was reduced significantly and was seen rarely in the nuclei (Fig. 
1). The positive expression rate of NF-κB was increased signifi-
cantly in the diabetic group and metformin-treated group than 
in the control group. There was no difference in NF-κB-positive 
nuclei in the control group and aspirin-treated group (Table 2).
Western blot analysis
NF-κB p65 was not expressed or weakly expressed in normal 
control group. The positive expression rate of NF-κB p65 was sig-
nificantly higher in diabetic and metformin-treated group than 
in normal control and aspirin-treated group. There were no sig-
nificant differences between normal control and aspirin-treat-
ed group (Fig. 2).
Correlation analysis 
HOMA-IR had a positive correlation with the level of serum TNF- 
α (r = 0.790, P < 0.01), and with NF-κB expression (r = 0.799, P < 
0.001). The level of serum TNF-α had a positive correlation with 
NF-κB expression (r = 0.964, P < 0.001). 
DISCUSSION
In this study, we provided evidence that aspirin improves insu-
lin resistance by inhibiting hepatic NF-κB activation and TNF-α 
level in streptozotocin-induced type 2 diabetic rats. Insulin re-
sistance is not only an initiating pathogenic but also a major fac-
tor that promotes the development of type 2 diabetic. Overt dia-
betes is thought to be preceded by a long period of insulin resis-
tance, during which sufficient insulin is produced to maintain 
normal or near-normal glucose tolerance. However, this chron-
ic compensatory insulin hypersecretion to overcome tissue in-
sensitivity can itself finally lead to pancreatic beta cell failure 
and overt hyperglycemia (4, 15). In the present study, the group 
of streptozotocin-induced type 2 diabetes rats showed signifi-
cant increase in fasting plasma glucose, insulin, and HOMA-IR 
value when compared to the normal control group, which indi-
cated development of insulin resistance. 
  Since Pickup et al. (16) first proposed diabetes is an inflam-
matory disease state in 1997, growing evidence has pointed to a 
correlation between various proinflammatory cytokines and 
insulin resistance/type 2 diabetes (17-19). Recent data have re-
vealed that adipocyte-derived TNF-α, an inflammatory cytokine 
produced mainly by monocytes and macrophages was increased 
in the insulin resistant states of obesity and type 2 diabetes. In 
our study we also found that serum TNF-α was increased in di-
abetic group and positively correlated with insulin resistance. 
Thus, TNF-α has been recognized as an important mediator for 
insulin resistance by impairing insulin signaling. Specifically, 
TNF-α can decrease glucose uptake and utilization of peripher-
al tissues by targeting insulin signaling pathways and glucose 
transporter 4 (GLUT4). The mechanism of the decrease is due 
to stimulation of serine phosphorylation of IRS1 and IRS2, in-
hibiting tyrosine kinase activity of the insulin receptor and phos-
phatidylinositol-3-kinase (PI3K) signaling pathways (20). 
  NF-κB is a proinflammatory master switch that controls the 
production of a host of inflammatory markers and mediators, 
including TNF-α, IL-6, CRP, and PAI-1. Many studies suggest that 
NF-κB is closely related to the development of insulin resistance 
of type 2 diabetic (9, 10, 21). The mechanism of NF-κB causing 
insulin resistance has not studied thoroughly but studies have 
found that NF-κB can be activated by sustained high blood sug-
ar (22). In addition, activation of the NF-κB induces the expres-
sion of many inflammatory cytokines such as TNF-α, IL-6, which 
are crucial factors in insulin resistance. Finally, TNF-α is not only 
induced by NF-κB, but also a strong activator of NF-κB. TNF-α 
binding induces activation of the IKK kinases, which regulates 
NF-κB transcriptional activity, finally leading to degradation of 
IRS, inhibition of tyrosine phosphorylation, and limit for signal 
transmission from the insulin receptor to PI3K (23). In our study 
we also found that TNF-α was increased accompanied by in-
Table 2. NF-κB nuclei positive expression rate and optical density in liver tissue by 
immunohistochemistry in the studied groups (n = 9)
Groups Positive expression rate (%) Optical density
Control  9.63 ± 2.45 0.100 ± 0.041
Diabetic  26.73 ± 5.74* 0.668 ± 0.087*
Apirin-treated  7.73 ± 3.56
†,‡ 0.300 ± 0.089
†,‡
Metformin-treated 25.29 ± 6.86* 0.555 ± 0.057*
,†
Data are shown as mean ± SD. *P < 0.001, compared to control group; 
†P < 0.001, 
compared to diabetic group; 
‡P < 0.001, compared to metformin-treated group.
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Fig. 2. Western blot analyses of NF-κB (p65) of liver tissues from four studied groups. 
Lane 1, control group; Lane 2, diabetic group; Lane 3, aspirin-treated group; Lane 4, 
metformin-treated group. *P < 0.001, compared to control group; 
†P < 0.001, com-
pared to diabetic group.Sun X, et al.  •  Effect of Aspirin on Hepatocyte NF-κB and Serum TNF-α 
http://jkms.org   769 DOI: 10.3346/jkms.2011.26.6.765
creased expression of hepatic NF-κB in the diabetic group. How-
ever, TNF-α was decreased and hepatic NF-κB expression was 
reduced after aspirin treatment. These suggest that NF-κB acti-
vation promotes TNF-α secretion and increased TNF-α level 
further stimulates the NF-κB activation, the two of which form 
a positive feedback loop and promote severe insulin resistance. 
After aspirin intervention, inhibition of NF-κB expression also 
reduced TNF-α level and improved the insulin resistance. 
  The liver is the key organ of insulin resistance in type 2 diabe-
tes. Decreased hepatic insulin sensitivity may lead to increased 
hepatic gluconeogenesis, postprandial hyperinsulinemia and 
increased formation of triglycerides in the liver cells. In our study, 
we found that hepatocytes became larger and showed glycogen 
deposition in the cytoplasm. Immunohistochemistry showed 
hepatocyte NF-κB was expressed both in the cytoplasm and nu-
clei in the diabetic group and the metformin-treated group. West-
ern blot showed the positive expression rate of NF-κB p65 was 
significantly higher in diabetic and metformin-treated group 
than in control group. These suggest that an up-regulation of 
hepatocyte NF-κB is strongly associated with systemic insulin 
resistance, which is consistent with pervious two studies (9, 10), 
indicating that IKK-β and NF-κB play important roles in the prog-
ress of hepatic insulin resistance. These two findings also indi-
cate that lipid accumulation in the liver leads to hepatic ‘inflam-
mation’ through NF-κB activation and downstream cytokine 
production, upregulates TNF-α production and secretion. TNF-α 
works locally through paracrine and/or endocrine mechanisms 
to activate TNF-α signaling in the liver. Given that the link be-
tween insulin resistance and inflammation, limiting inflamma-
tion and reducing levels of inflammatory markers may be a 
promising therapeutic strategy. Aspirin, one of the most widely 
used medications in the world, has been used to analgesic, an-
tipyretic, and anti-inflammatory for more than 100 yr. In recent 
years, aspirin was found not only to have anti-platelet aggrega-
tion and prevent cardiovascular diseases, but also have a role in 
the reversal of obesity- and diet-induced insulin resistance (24). 
  In our study, we found that the aspirin-treated group showed 
significant reduction of serum insulin and HOMA-IR, indicat-
ing aspirin can improve insulin resistance. We also found that 
aspirin had significant therapeutic effect on improving blood 
lipids, although the hypoglycemic effect was not obvious. The 
mechanism of aspirin improving insulin resistance has not been 
studied clearly. Previous studies showed that aspirin can pre-
vent NF-κB activation by inhibiting IKK activation and dissocia-
tion of NF-κB from IκB (4), so that NF-κB cannot control the 
downstream expression of inflammatory cytokines, which re-
duce insulin resistance. In our study we also found that hepato-
cyte NF-κB was expressed both in the cytoplasm and nuclei in 
the diabetic group. But in the aspirin-treated group, hepatocyte 
NF-κB expression was reduced significantly and was seen rare-
ly in the nuclei. TNF-α levels were also decreased compared to 
diabetic groups. These suggest that aspirin improves insulin re-
sistance by inhibiting hepatic NF-κB activation and TNF-α level. 
  In conclusion, the inflammatory pathways hold a substantial 
part in insulin resistance of type 2 diabetes mellitus. Therefore, 
diabetes therapy should not only focus on glycemic control but 
also on the underlying mechanism to improve insulin resistance. 
Aspirin, an old drug for new use, offers unique approaches for 
the treatment of type 2 diabetes because of its insulin-sensitiz-
ing and anti-inflammatory properties. 
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Effect of Aspirin on the Expression of Hepatocyte NF-κB and Serum TNF-α in 
Streptozotocin-Induced Type 2 Diabetic Rats
Xiaodong Sun, Fang Han, Junling Yi, Lina Han and Ben Wang
We hypothesized that aspirin might improve insulin resistance in type 2 diabetes by inhibiting hepatic NF κB activation and serum 
TNF-α. Adult male Wistar rats were randomly divided into four groups: control, untreated diabetic, diabetic treated with 
metformin, and diabetic treated with aspirin. Diabetes was induced by high-fat feeding and a low dose of streptozotocin. Aspirin 
did not lowered fasting glucose level but significantly reduced hepatic NF-κB expression and serum TNF-α level with improved 
insulin resistance. The relevant analysis showed positive correlation between the expression of HOMA-IR and NF-κB, HOMA-IR and 
serum TNF-α. It is suggested that aspirin improves insulin resistance by inhibiting hepatic NF-κB activation and TNF-α level in 
streptozotocin-induced type 2 diabetic rats. Aspirin, an old drug for new use, might offer unique approaches for the treatment of 
type 2 diabetes.